NCT04913870

Angiotensin Receptor Blockers in Aortic Stenosis

Impact of Angiotensin Receptor Blockers in Aortic Stenosis - a Randomized Controlled Trial

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 144 (estimated)
• Sponsor: Institut universitaire de cardiologie et de pneumologie de Québec, University Laval · Academic / Other
• Sex: All
• Age: 20 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

This study is intended to investigate the effect of angiotensin receptor blockers (ARBs) on mild-to-moderate aortic stenosis.

Detailed description

Studies support the concept that activation of the renin-angiotensin system may be involved in the progression of valve stenosis and myocardial fibrosis in aortic stenosis. Furthermore recent studies have shown that renin-angiotensin system medication may slow down aortic stenosis progression rate and left ventricle remodeling. Thus the present study is a randomized control trial to test the efficacy of the angiotensin receptor blocker (ARB) to slow down aortic stenosis progression and left ventricular remodeling/dysfunction in patients with mild-to-moderate aortic stenosis.

Conditions

• Aortic Stenosis
• Aortic Valve Stenosis

Interventions

Type	Name	Description
DRUG	Angiotensin Receptor Blockers	Angiotensin Receptor Blockers treatment for 2 years.
OTHER	Placebo	Placebo administration for 2 years.

Timeline

• Start date: 2020-02-01
• Primary completion: 2027-02-01
• Completion: 2027-02-01
• First posted: 2021-06-04
• Last updated: 2024-12-20

Locations

2 sites across 2 countries: Canada, Denmark